Interleukin-6 (IL-6) is a pleiotropic cytokine implicated in the pathogenesis of 
many immune-mediated disorders including several types of non-infectious 
uveitis. These uveitic conditions include Vogt-Koyanagi-Harada syndrome, uveitis 
associated with Behçet disease, and sarcoidosis. This review summarizes the role 
of IL-6 in immunity, highlighting its effect on Th17, Th1, and plasmablast 
differentiation. It reviews the downstream mediators activated in the process of 
IL-6 binding to its receptor complex. This review also summarizes the biologics 
targeting either IL-6 or the IL-6 receptor, including tocilizumab, sarilumab, 
sirukumab, olokizumab, clazakizumab, and siltuximab. The target, dosage, 
potential side effects, and potential uses of these biologics are summarized in 
this article based on the existing literature. In summary, anti-IL-6 therapy for 
non-infectious uveitis shows promise in terms of efficacy and side effect 
profile.